您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > SR7826
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SR7826
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SR7826图片
CAS NO:1219728-20-7
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议

产品介绍
SR7826 是一类由双芳基脲衍生的有效,选择性和具有口服活性的 LIM 激酶 (LIMK) 抑制剂,对于LIMK1IC50为 43 nM。SR7826 对LIMK1的选择性比 ROCK 和 JNK 激酶高 100 倍以上。
生物活性

SR7826 is a class of bis-aryl urea derived potent, selective and orally activeLIM kinase (LIMK)inhibitor with anIC50of 43 nM forLIMK1. SR7826 is >100-fold more selective forLIMK1thanROCKandJNKkinases[1].

IC50& Target

LIMK1

43 nM (IC50)

ROCKI

5536 nM (IC50)

ROCKII

6565 nM (IC50)

体外研究
(In Vitro)

In the profiling against a panel of 61 kinases, SR7826 (compound 18b) at 1 μM inhibits only Limk1 and STK16 with ≥80% inhibition. SR7826 is highly efficient in inhibiting cell-invasion/migration in PC-3 cells. SR7826 (compound 18b) inhibits cofilin phosphorylation in A7r5 (IC50= 470 nM) and PC-3 cells (IC50< 1 μM)[1].
SR7826 (1 μM) inhibits contractions of prostate strips, which were induced by electrical field stimulation and inhibits cofilin phosphorylation in prostate tissues and cultured stromal cells (WPMY-1). In WPMY-1 cells, SR7826 causes breakdown of actin filaments and reduced viability[3].

体内研究
(In Vivo)

SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals[2].
The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a T1/2of 2.2h, an AUC of 8.4 μM*h and a Cmaxof 7.7 μM, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)[1].

Animal Model:hAPPJ20 mice (6-mouth-old)[2]
Dosage:10 mg/kg
Administration:Oral gavage; once daily; for 11 days
Result:Significantly reduced the phosphorylation of cofilin at Ser3, a LIMK1 substrate.
分子量

387.43

性状

Solid

Formula

C22H21N5O2

CAS 号

1219728-20-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL(258.11 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.5811 mL12.9056 mL25.8111 mL
5 mM0.5162 mL2.5811 mL5.1622 mL
10 mM0.2581 mL1.2906 mL2.5811 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: 2.5 mg/mL (6.45 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (6.45 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 2.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.45 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。